Key facts
- This page summarizes John Northcott's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 May 2022, 21:33.
John Northcott - 16 May 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)
- Reporting relationship
- SVP & Chief Commercial Officer
- Issuer ticker
- NKTR
- Reported as of
- 16 May 2022
- Net transaction value
- -$18,138
- SEC form
- 4
- Accepted by SEC
- 17 May 2022, 21:33:45 UTC
- Prior SEC filing
- 18 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- Mark A. Wilson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John Northcott filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 17 May 2022.
Change
- Previous filing in this sequence was filed on 18 Feb 2022.
- Current net transaction value: -$18,138.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NKTR
transaction
Common Stock
Sale
- Transaction value
- $18,138
- Shares
- -4,592
- Change %
- -2%
- Price
- $3.95
- Shares after
- 223,210
- Date
- 16 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.